Transcriptional positive cofactor 4 promotes breast cancer proliferation and metastasis through c-Myc mediated Warburg effect
Transcriptional Activation
0301 basic medicine
Epithelial-Mesenchymal Transition
Proliferation
Cell Respiration
Breast Neoplasms
Metastasis
Proto-Oncogene Proteins c-myc
03 medical and health sciences
Breast cancer
Cell Movement
Mice, Inbred NOD
Cell Line, Tumor
C-Myc
Animals
Humans
Neoplasm Metastasis
PC4
Cell Proliferation
QH573-671
Research
R
3. Good health
DNA-Binding Proteins
Cell Transformation, Neoplastic
Medicine
Heterografts
Female
Warburg effect
Cytology
Signal Transduction
Transcription Factors
DOI:
10.1186/s12964-019-0348-0
Publication Date:
2019-04-16T15:04:04Z
AUTHORS (12)
ABSTRACT
The human positive cofactor 4 (PC4) is initially identified as a transcriptional cofactor and has an important role in embryonic development and malignant transformation. However, the clinical significance and the molecular mechanisms of PC4 in breast cancer development and progression are still unknown.We investigated PC4 expression in 114 cases of primary breast cancer and matched normal breast tissue specimens, and studied the impact of PC4 expression as well as the molecular mechanisms of this altered expression on breast cancer growth and metastasis both in vitro and in vivo.PC4 was significantly upregulated in breast cancer and high PC4 expression was positively correlated with metastasis and poor prognosis of patients. Gene set enrichment analysis (GSEA) demonstrated that the gene sets of cell proliferation and Epithelial-Mesenchymal Transition (EMT) were positively correlated with elevated PC4 expression. Consistently, loss of PC4 markedly inhibited the growth and metastasis of breast cancer both in vitro and in vivo. Mechanistically, PC4 exerted its oncogenic functions by directly binding to c-Myc promoters and inducing Warburg effect.Our study reveals for the first time that PC4 promotes breast cancer progression by directly regulating c-Myc transcription to promote Warburg effect, implying a novel therapeutic target for breast cancer.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (57)
CITATIONS (22)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....